Drug Profile

Research programme: bispecific antibody drug conjugates - Zymeworks

Alternative Names: Biparatopic HER2 antibody; ZW 33

Latest Information Update: 28 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zymeworks
Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

28 Mar 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in Canada
28 Feb 2020 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV)
06 Nov 2018 Zymeworks plans a phase I trial for ZW 49 in early 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com